Reckitt Benckiser, UK owner of the global drug brand Nurofen has been ordered by an Australian court to stop selling different variations of the ibuprofen-based drug.
According to independent.co.uk, Nurofen has been marketed in different ways to relieve specific types of pain when in fact, all Nurofen products contain the exact same amount of the drug's active ingredient, ibuprofen lysine.
Australia's consumer watchdog,The Australian Competition and Consumer Commission (ACCC), has insisted that these specifically branded Nurofen products for back pain, period pain, tension headaches and migraine pain are misleading to the consumer and are no more or less effective in treating symptoms.
The UK owner has been ordered by Judge Edelman to remove the products from Australian shelves over the next three months.
As reported by independent.co.uk, Nurofen spokeswoman Montse Pena said in a statement that the drug company did not set out to mislead consumers.
© 2015 European Supermarket Magazine – your source for the latest retail news. Article by Ciara Mooney. To subscribe to ESM: The European Supermarket Magazine, click here.
